Key Points
- Director Scott Ward bought 73,255 shares of InspireMD at $1.15 each, spending about $84,243 and increasing his position by 44.71%.
- InspireMD stock was trading near its 52-week low at $1.15, with a market cap of $53.93 million and a negative earnings ratio, reflecting ongoing pressure on the shares.
- Wall Street remains cautiously upbeat: the stock has a consensus Buy rating and an average price target of $4.50, well above the current share price.
InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Scott Ward purchased 15,995 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average price of $1.15 per share, for a total transaction of $18,394.25. Following the completion of the purchase, the director directly owned 163,841 shares in the company, valued at $188,417.15. This represents a 10.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
InspireMD Stock Performance
NYSE NSPR opened at $1.15 on Friday. The firm has a market cap of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. InspireMD, Inc. has a one year low of $1.02 and a one year high of $2.93. The firm's fifty day moving average is $1.51 and its two-hundred day moving average is $1.75.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of InspireMD during the fourth quarter worth about $30,000. Virtu Financial LLC acquired a new position in shares of InspireMD during the fourth quarter worth about $31,000. Creative Planning acquired a new position in shares of InspireMD during the second quarter worth about $44,000. Legato Capital Management LLC acquired a new position in shares of InspireMD during the fourth quarter worth about $48,000. Finally, Uniting Wealth Partners LLC acquired a new position in shares of InspireMD during the third quarter worth about $51,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research analysts have commented on NSPR shares. Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research note on Monday. Maxim Group started coverage on shares of InspireMD in a research note on Monday, February 2nd. They issued a "buy" rating and a $6.00 price objective on the stock. Piper Sandler restated an "overweight" rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research note on Tuesday. Finally, Loop Capital set a $5.00 price objective on shares of InspireMD in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $4.50.
Get Our Latest Report on NSPR
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
